Brompheniramine

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Greece: Antiflam, Dimergan, Trates.

North America

USA: B-Vex, Brovex, Lodrane, LoHist-12, Tanacof, Vazol.

Drug combinations

Brompheniramine and Pseudoephedrine

Brompheniramine, Dextromethorphan, and Pseudoephedrine

Brompheniramine, Acetaminophen, Ascorbic Acid (Vitamin C), and Caffeine

Chemistry

Brompheniramine Maleate: C~16~H~19~BrN~2~ C~4~H~4~O~4~. Mw: 435.31. (1) 2-Pyridinepropanamine, γ-(4-bromophenyl)-N,N-dimethyl-, (±)-, (Z)-butenedioate (1:1); (2)(±)-2-p-Bromo-α-2-(dimethylamino)ethylbenzylpyridine maleate (1:1). CAS-980-71-2; CAS-86-22-6 (brompheniramine).

Pharmacologic Category

First Generation Antihistamines; Histamine H~1~ Antagonist. (ATC-Code: R06AB01).

Mechanism of action

Competes with histamine for H~1~-receptor sites on effector cells.

Therapeutic use

Symptomatic relief of perennial and seasonal allergic rhinitis, vasomotor rhinitis, and other respiratory allergies.

Pregnancy and lactiation implications

There are no adequate studies in pregnant women. May cause severe reactions (convulsions) in newborns and premature infants (avoid use in 3^rd^ trimester). Use in pregnancy only when clearly needed. Not recommended during lactation.

Unlabeled use

Contraindications

Hypersensitivity to brompheniramine or any component of the formulation. Use with or within 14 days of MAO inhibitor therapy. Narrow-angle glaucoma. Urinary retention. Peptic ulcer disease. During acute asthmatic attacks.

Warnings and precautions

May cause CNS depression. Effects may be potentiated when used with other sedative drugs or ethanol. May cause agitation, confusion, dizziness, drowsiness, or fatigue. May cause paradoxical excitation in pediatric patients. May cause hallucinations in overdose. Concurrent use with psychotropics may produce additive anticholinergic and/or sedative effects. Caution in history of asthma, cardiovascular disease (including hypertension and ischemic heart disease), increased intraocular pressure, prostatic hyperplasia and/or urinary obstruction, or thyroid dysfunction. Some products may contain phenylalanine or tartrazine. May interfere with skin tests using allergen extracts. May cause xerostomia (mainly in elderly). Tablets are to be swallowed whole.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart